首页 > 最新文献

Blood Transfusion最新文献

英文 中文
Which should be the target for preoperative hemoglobin optimization? 术前优化血红蛋白的目标是什么？
IF 2.4 3区 医学 Q2 HEMATOLOGY
Blood Transfusion
Pub Date : 2024-11-22 DOI: 10.2450/BloodTransfus.945
Daniel Ariza-Villanueva, Donat R Spahn, Andrés Cobos-Díaz
{"title":"Which should be the target for preoperative hemoglobin optimization?","authors":"Daniel Ariza-Villanueva, Donat R Spahn, Andrés Cobos-Díaz","doi":"10.2450/BloodTransfus.945","DOIUrl":"https://doi.org/10.2450/BloodTransfus.945","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physiologic transfusion thresholds, better than using Hb-based thresholds? 生理输血阈值优于基于血液学的阈值？
IF 2.4 3区 医学 Q2 HEMATOLOGY
Blood Transfusion
Pub Date : 2024-11-22 DOI: 10.2450/BloodTransfus.901
Matthias Noitz, Martin W Dünser, Tina Tomić Mahečić, Jens Meier
{"title":"Physiologic transfusion thresholds, better than using Hb-based thresholds?","authors":"Matthias Noitz, Martin W Dünser, Tina Tomić Mahečić, Jens Meier","doi":"10.2450/BloodTransfus.901","DOIUrl":"https://doi.org/10.2450/BloodTransfus.901","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142773899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Viscoelastic monitoring of direct oral anticoagulants (DOAC). 直接口服抗凝剂（DOAC）的粘弹性监测。
IF 2.4 3区 医学 Q2 HEMATOLOGY
Blood Transfusion
Pub Date : 2024-11-22 DOI: 10.2450/BloodTransfus.867
Lidia Mora, Laura Pons-Pellicé, Manuel Quintana-Díaz
{"title":"Viscoelastic monitoring of direct oral anticoagulants (DOAC).","authors":"Lidia Mora, Laura Pons-Pellicé, Manuel Quintana-Díaz","doi":"10.2450/BloodTransfus.867","DOIUrl":"https://doi.org/10.2450/BloodTransfus.867","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142774057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PBM and ERAS: mandatory bedfellows. PBM和ERAS：强制性的同床异梦。
IF 2.4 3区 医学 Q2 HEMATOLOGY
Blood Transfusion
Pub Date : 2024-11-22 DOI: 10.2450/BloodTransfus.876
Henrik Kehlet
{"title":"PBM and ERAS: mandatory bedfellows.","authors":"Henrik Kehlet","doi":"10.2450/BloodTransfus.876","DOIUrl":"https://doi.org/10.2450/BloodTransfus.876","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142773896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anemia is a disease, not a number. 贫血是一种疾病，而不是一个数字。
IF 2.4 3区 医学 Q2 HEMATOLOGY
Blood Transfusion
Pub Date : 2024-11-22 DOI: 10.2450/BloodTransfus.897
Shane C Coy, Matthew A Warner
{"title":"Anemia is a disease, not a number.","authors":"Shane C Coy, Matthew A Warner","doi":"10.2450/BloodTransfus.897","DOIUrl":"https://doi.org/10.2450/BloodTransfus.897","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142773715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Restrictive versus liberal transfusion thresholds: lights and shadow. 限制性与自由输血阈值：光明与阴影。
IF 2.4 3区 医学 Q2 HEMATOLOGY
Blood Transfusion
Pub Date : 2024-11-22 DOI: 10.2450/BloodTransfus.884
Massimo Franchini, Matteo Zani, Daniele Focosi
{"title":"Restrictive versus liberal transfusion thresholds: lights and shadow.","authors":"Massimo Franchini, Matteo Zani, Daniele Focosi","doi":"10.2450/BloodTransfus.884","DOIUrl":"https://doi.org/10.2450/BloodTransfus.884","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142773943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Postoperative anemia: is there a role for iron replacement therapy? 术后贫血：铁替代治疗是否有作用？
IF 2.4 3区 医学 Q2 HEMATOLOGY
Blood Transfusion
Pub Date : 2024-11-22 DOI: 10.2450/BloodTransfus.906
Elvira Bisbe
{"title":"Postoperative anemia: is there a role for iron replacement therapy?","authors":"Elvira Bisbe","doi":"10.2450/BloodTransfus.906","DOIUrl":"https://doi.org/10.2450/BloodTransfus.906","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142773906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reticulocyte hemoglobin in the evaluation of erythropoietic activity and iron availability. 网织红细胞血红蛋白在红细胞生成活性和铁可用性的评价。
IF 2.4 3区 医学 Q2 HEMATOLOGY
Blood Transfusion
Pub Date : 2024-11-22 DOI: 10.2450/BloodTransfus.893
Eloísa Urrechaga, Mónica Fernández
{"title":"Reticulocyte hemoglobin in the evaluation of erythropoietic activity and iron availability.","authors":"Eloísa Urrechaga, Mónica Fernández","doi":"10.2450/BloodTransfus.893","DOIUrl":"https://doi.org/10.2450/BloodTransfus.893","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142773945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SARS-CoV-2 infection rebound among patients receiving antiviral agents, convalescent plasma, or no treatment: a systematic review with meta-analysis. 接受抗病毒药物、康复血浆或不接受治疗的患者中 SARS-CoV-2 感染的反弹：系统回顾与荟萃分析。
IF 2.4 3区 医学 Q2 HEMATOLOGY
Blood Transfusion
Pub Date : 2024-11-01 Epub Date: 2024-05-27 DOI: 10.2450/BloodTransfus.764
Mario Cruciani, Ilaria Pati, Francesca Masiello, Vanessa Piccinini, Simonetta Pupella, Vincenzo De Angelis

Background: There is some evidence showing rebound of COVID-19 infections in patients treated with nirmatrelvir-ritonavir between 2 and 8 days following cessation of the antiviral treatment. COVID-19 rebound is not unique to patients treated with nirmatrelvir-ritonavir, but is also observed in molnupiravir recipients, in patients who did not receive any antiviral treatment and in patients who received convalescent plasma (CP).

Materials and methods: This was a systematic review with meta-analysis of clinical trials evaluating rates of virologic and clinical rebound in COVID-19 patients receiving antiviral agents, CP or no treatment. Both randomized clinical trials and controlled cohort studies were considered. The methodological quality of trials was assessed using ROB-2 and ROBIN-1 checklists, and the GRADE approach.

Results: Data were available from 16 trials. The occurrence of virologic rebound was more commonly observed among nirmatrelvir recipients than among untreated patients (relative risk [RR]=2.12; 95% confidence interval [CI]: 1.38-3.28; p=0.0007). No differences were observed in the occurrence of virologic rebound between nirmatrelvir-ritonavir and molnupiravir recipients (RR=1.01; 95% CI: 0.71-1.43). Similar rates of virologic rebounds were observed in molnupiravir recipients and untreated patients (RR=1.14; 95% CI: 0.81-1.6). One study in the pre-omicron period compared rates of virologic rebound between patients receiving standard of care with or without CP: no differences were observed between groups (RR=1.04; 95% CI: 0.55-1.99). Rates of clinical rebound were reported in seven trials, five evaluating nirmatrelvir-ritonavir and untreated patients, and two evaluating nirmatrelvir-ritonavir and molnupiravir recipients. No statistically significant differences between groups were observed. For all these comparisons, the certainty of the available evidence was graded as low or moderate.

Discussion: Virologic rebound of COVID-19 infections appears to be mild and self-limited, and was observed more commonly in nirmatrelvir-ritonavir recipients than in untreated patients, but was also observed in patients treated with molnupiravir or CP.

背景：有证据显示，在停止抗病毒治疗后的 2 到 8 天内，接受尼马瑞韦-利托那韦治疗的患者会出现 COVID-19 感染反弹。COVID-19反弹并不是尼马瑞韦-利托那韦治疗患者所独有的，在接受莫仑吡韦治疗的患者、未接受任何抗病毒治疗的患者以及接受康复血浆（CP）治疗的患者中也可观察到COVID-19反弹：这是一项系统性回顾和荟萃分析临床试验，评估了接受抗病毒药物、CP 或未接受治疗的 COVID-19 患者的病毒学和临床反弹率。随机临床试验和对照队列研究均在考虑之列。采用ROB-2和ROBIN-1检查表以及GRADE方法对试验的方法学质量进行了评估：结果：16 项试验提供了数据。与未经治疗的患者相比，接受尼尔马特韦治疗的患者更容易出现病毒学反弹（相对风险 [RR]=2.12; 95% 置信区间 [CI]: 1.38-3.28; p=0.0007）。尼马瑞韦-利托那韦和molnupiravir受试者之间的病毒学反弹发生率没有差异（RR=1.01；95% CI：0.71-1.43）。在接受莫仑吡拉韦治疗的患者和未接受治疗的患者中观察到相似的病毒学反弹率（RR=1.14；95% CI：0.81-1.6）。有一项研究比较了接受标准治疗和未接受 CP 治疗的患者的病毒学反弹率：未观察到组间差异（RR=1.04；95% CI：0.55-1.99）。有七项试验报告了临床反弹率，其中五项评估了接受奈马瑞韦-利托那韦治疗的患者和未接受治疗的患者，两项评估了接受奈马瑞韦-利托那韦治疗的患者和接受莫仑匹拉韦治疗的患者。没有观察到组间有明显的统计学差异。在所有这些比较中，现有证据的确定性被评为低度或中度：讨论：COVID-19感染的病毒学反弹似乎是轻微的、自限性的，与未接受过治疗的患者相比，在接受过尼马瑞韦-利托那韦治疗的患者中更常观察到这种反弹，但在接受过莫仑吡韦或CP治疗的患者中也可观察到这种反弹。
{"title":"SARS-CoV-2 infection rebound among patients receiving antiviral agents, convalescent plasma, or no treatment: a systematic review with meta-analysis.","authors":"Mario Cruciani, Ilaria Pati, Francesca Masiello, Vanessa Piccinini, Simonetta Pupella, Vincenzo De Angelis","doi":"10.2450/BloodTransfus.764","DOIUrl":"10.2450/BloodTransfus.764","url":null,"abstract":"<p><strong>Background: </strong>There is some evidence showing rebound of COVID-19 infections in patients treated with nirmatrelvir-ritonavir between 2 and 8 days following cessation of the antiviral treatment. COVID-19 rebound is not unique to patients treated with nirmatrelvir-ritonavir, but is also observed in molnupiravir recipients, in patients who did not receive any antiviral treatment and in patients who received convalescent plasma (CP).</p><p><strong>Materials and methods: </strong>This was a systematic review with meta-analysis of clinical trials evaluating rates of virologic and clinical rebound in COVID-19 patients receiving antiviral agents, CP or no treatment. Both randomized clinical trials and controlled cohort studies were considered. The methodological quality of trials was assessed using ROB-2 and ROBIN-1 checklists, and the GRADE approach.</p><p><strong>Results: </strong>Data were available from 16 trials. The occurrence of virologic rebound was more commonly observed among nirmatrelvir recipients than among untreated patients (relative risk [RR]=2.12; 95% confidence interval [CI]: 1.38-3.28; p=0.0007). No differences were observed in the occurrence of virologic rebound between nirmatrelvir-ritonavir and molnupiravir recipients (RR=1.01; 95% CI: 0.71-1.43). Similar rates of virologic rebounds were observed in molnupiravir recipients and untreated patients (RR=1.14; 95% CI: 0.81-1.6). One study in the pre-omicron period compared rates of virologic rebound between patients receiving standard of care with or without CP: no differences were observed between groups (RR=1.04; 95% CI: 0.55-1.99). Rates of clinical rebound were reported in seven trials, five evaluating nirmatrelvir-ritonavir and untreated patients, and two evaluating nirmatrelvir-ritonavir and molnupiravir recipients. No statistically significant differences between groups were observed. For all these comparisons, the certainty of the available evidence was graded as low or moderate.</p><p><strong>Discussion: </strong>Virologic rebound of COVID-19 infections appears to be mild and self-limited, and was observed more commonly in nirmatrelvir-ritonavir recipients than in untreated patients, but was also observed in patients treated with molnupiravir or CP.</p>","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"537-550"},"PeriodicalIF":2.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrent disease after a matched sibling hematopoietic transplant in an aplastic anemia patient with a disease risk allele, HLA-B*40:02. 一名再生障碍性贫血患者在接受配型成功的同胞造血移植后病情复发，而该患者具有患病风险等位基因 HLA-B*40:02。
IF 2.4 3区 医学 Q2 HEMATOLOGY
Blood Transfusion
Pub Date : 2024-11-01 Epub Date: 2024-08-26 DOI: 10.2450/BloodTransfus.674
Akshita Khosla, Yoshitaka Inoue, Joseph Cioccio, Kevin Rakszawski, Natthapol Songdej, Myles Nickolich, Hong Zheng, Seema Naik, Christopher Ehmann, David Claxton, Witold Rybka, Jeffrey Sivik, Joseph Mierski, Brooke Silar, Caitlin Vajdic, Raymond Hohl, Hiroko Shike, Shin Mineishi, Kentaro Minagawa
{"title":"Recurrent disease after a matched sibling hematopoietic transplant in an aplastic anemia patient with a disease risk allele, HLA-B*40:02.","authors":"Akshita Khosla, Yoshitaka Inoue, Joseph Cioccio, Kevin Rakszawski, Natthapol Songdej, Myles Nickolich, Hong Zheng, Seema Naik, Christopher Ehmann, David Claxton, Witold Rybka, Jeffrey Sivik, Joseph Mierski, Brooke Silar, Caitlin Vajdic, Raymond Hohl, Hiroko Shike, Shin Mineishi, Kentaro Minagawa","doi":"10.2450/BloodTransfus.674","DOIUrl":"10.2450/BloodTransfus.674","url":null,"abstract":"","PeriodicalId":49260,"journal":{"name":"Blood Transfusion","volume":" ","pages":"525-528"},"PeriodicalIF":2.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142511373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Blood Transfusion
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1